Business
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of
About this update from Artelo Biosciences, Inc.
[{"type":"text","content":"Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 (“GLP-1”) receptor agonist therapy. The initiative is supported by four significant developments: observations of a muscle protective effect in the CAReS trial when ART27.13 was given to patients with cancer anorexia and cachexia (shown by improvements in lean body mass and physical activity) and in preclinical research of cancer cachexia (reversal of myotoxic effects of cancer caused by CB2 activation) conducted by Professor Richard Porter at Trinity College Dublin, Ireland;publication of independent peer-reviewed research validating the differentiated pharmacology of ART27.13 compared to other CB2 agonists and supporting its potential utility in muscle preservation;filing of a provisional patent application covering the use of cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy; andinitiation of a non-clinical study to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation. These positive early developments position ART27.13 as a potential companion therapy candidate for one of the most important and fastest-growing categories in biopharma. J.P. Morgan recently projected the global incretin market, which includes GLP-1 medicines, could reach $200 billion by 2030, while estimating approximately 25 million Americans could be receiving GLP-1 treatment by 2030. As use of GLP-1-based medicines continues to expand, published analyses have reported that loss of lean body mass may account for a meaningful proportion of total weight lost with GLP-1-based therapies, highlighting an unmet need for muscle preservation. “GLP-1 medicines are reshaping the treatment landscape for obesity and metabolic disease, yet preservation of muscle and lean body mass remains a critical issue for pat...